Phase 3 Readout~month

Phase 3 Topline: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants

June 1, 2029

Company: EXELIXIS, INC. (EXEL)
Drug: zanzalintinib
Indication: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)

Other upcoming events for EXEL

Patent ExpiryPatent/Exclusivity Expiry: SUPREP BOWEL PREP KIT

Patent ExpiryPatent/Exclusivity Expiry: XYWAV

Patent ExpiryPatent/Exclusivity Expiry: PREPOPIK

Patent ExpiryPatent/Exclusivity Expiry: OFEV

Phase 3 ReadoutPhase 3 Topline: Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants — EXEL Phase 3 Readout | BioSniper